NCT07422233

Brief Summary

This prospective interventional study was conducted between 2023 and 2025 at the Department of Neurology of Bouali Sina Hospital. Consecutive elderly patients presenting with epilepsy were screened for eligibility. The diagnosis of epilepsy was confirmed by the treating neurologist. The patients underwent treatment with levetiracetam. Primary and secondary outcomes were investigated as was explained before.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
137

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Sep 2023

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 13, 2023

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
20 days until next milestone

Study Completion

Last participant's last visit for all outcomes

January 20, 2026

Completed
16 days until next milestone

First Submitted

Initial submission to the registry

February 5, 2026

Completed
14 days until next milestone

First Posted

Study publicly available on registry

February 19, 2026

Completed
Last Updated

February 19, 2026

Status Verified

February 1, 2026

Enrollment Period

2.3 years

First QC Date

February 5, 2026

Last Update Submit

February 12, 2026

Conditions

EpilepsyElderly

Outcome Measures

Primary Outcomes (4)

  • Seizure free rate

    The rate of patients who stayed seizure-free after drug initiation

    12 months

  • Retention rate

    The rate of patients who continue taking drug

    12 months

  • Time to first seizure

    The interval between starting drug and recurrence of seizure

    at occurrence of first seizure

  • Time to withdrawal

    The interval between starting drug and stoping its use

    the day that the patient stops taking drug

Secondary Outcomes (1)

  • Tolerability rate

    12 months

Study Arms (1)

Levetiracetam

OTHER

Elderly patients with epilepsy who have received levetiracetam

Drug: Oral levetiracetam

Interventions

Oral levetiracetamDRUG

Treatment with levetiracetam tablets

Levetiracetam

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥60 years
  • Diagnosis of epilepsy

You may not qualify if:

  • Chronic kidney disease requiring dialysis
  • History of psychotic disorders or current use of anxiolytic, antidepressant, or antipsychotic medications
  • Current use of antiseizure medications for any reason

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mazandaran University of medical sciences

Sari, Mazandaran, 4815733971, Iran

Location

MeSH Terms

Conditions

Epilepsy

Interventions

Levetiracetam

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

AcetamidesAmidesOrganic ChemicalsAcetatesAcids, AcyclicCarboxylic AcidsPyrrolidinonesPyrrolidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Associate professor of neurology

Study Record Dates

First Submitted

February 5, 2026

First Posted

February 19, 2026

Study Start

September 13, 2023

Primary Completion

December 31, 2025

Study Completion

January 20, 2026

Last Updated

February 19, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

If requested in certain circumstances.

Locations

IR(1)